MA51418A - Inhibiteurs de glycolate oxydase pour le traitement de maladies - Google Patents

Inhibiteurs de glycolate oxydase pour le traitement de maladies

Info

Publication number
MA51418A
MA51418A MA051418A MA51418A MA51418A MA 51418 A MA51418 A MA 51418A MA 051418 A MA051418 A MA 051418A MA 51418 A MA51418 A MA 51418A MA 51418 A MA51418 A MA 51418A
Authority
MA
Morocco
Prior art keywords
diseases
treatment
oxidase inhibitors
glycolate oxidase
glycolate
Prior art date
Application number
MA051418A
Other languages
English (en)
Inventor
Qi Chao
Bing Wang
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MA51418A publication Critical patent/MA51418A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051418A 2017-12-29 2018-12-28 Inhibiteurs de glycolate oxydase pour le traitement de maladies MA51418A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762611995P 2017-12-29 2017-12-29
US201862765313P 2018-08-20 2018-08-20

Publications (1)

Publication Number Publication Date
MA51418A true MA51418A (fr) 2020-11-04

Family

ID=65234672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051418A MA51418A (fr) 2017-12-29 2018-12-28 Inhibiteurs de glycolate oxydase pour le traitement de maladies

Country Status (17)

Country Link
US (3) US11384055B2 (fr)
EP (1) EP3732167A2 (fr)
JP (2) JP7344878B2 (fr)
KR (1) KR20200112860A (fr)
CN (6) CN117069713A (fr)
AR (1) AR114070A1 (fr)
AU (1) AU2018395275A1 (fr)
BR (1) BR112020013073A2 (fr)
CA (1) CA3086401A1 (fr)
CL (1) CL2020001742A1 (fr)
IL (3) IL297788A (fr)
MA (1) MA51418A (fr)
MX (6) MX2020006414A (fr)
PE (1) PE20201500A1 (fr)
SG (1) SG11202005807QA (fr)
TW (2) TWI811282B (fr)
WO (1) WO2019133770A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020013073A2 (pt) * 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
WO2019165159A1 (fr) 2018-02-23 2019-08-29 Oxalurx, Inc. Composés et méthodes de traitement de maladies liées à l'oxalate
IL279952B2 (en) * 2018-07-06 2024-11-01 Cantero Therapeutics Inc Triazole glycolate oxidase inhibitors
BR112022003358A2 (pt) 2019-08-22 2022-05-17 Oxalurx Inc Composto, composição farmacêutica, método para inibir atividade de glicolato oxidase (gox) em uma amostra biológica, método para tratar uma doença relacionada ao oxalato em um indivíduo que necessita do mesmo, e uso de um composto
WO2021086874A1 (fr) * 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Carboxylates hétérocycles en tant qu'inhibiteurs de glycolate oxydase
WO2021142155A1 (fr) * 2020-01-08 2021-07-15 Orfan Biotech Inc. Procédés de préparation d'inhibiteurs de glycolate oxydase de triazole
CN115702146B (zh) * 2020-06-30 2024-10-18 苏州恩华生物医药科技有限公司 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
WO2022066933A1 (fr) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Composés triazolyl substitués de pentafluoro-sulfanyl et procédés d'utilisation associés
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法
WO2023170024A1 (fr) * 2022-03-11 2023-09-14 University Of Copenhagen Modulateurs de camk2 et leur utilisation en médecine
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
WO2024109917A1 (fr) * 2022-11-25 2024-05-30 西藏海思科制药有限公司 Dérivé de triazole et son application en médecine
WO2024212137A1 (fr) * 2023-04-12 2024-10-17 Cantero Therapeutics, Inc. Formes cristallines d'un composé d'acide 1h-1, 2, 3-triazole-4-carboxylique
WO2025206002A1 (fr) * 2024-03-28 2025-10-02 日本曹達株式会社 Composé de triazole et microbicide pour une utilisation agricole ou horticole

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US149223A (en) * 1874-03-31 Improvement in axles for vehicles
DE2860722D1 (en) * 1977-11-10 1981-08-27 Beecham Group Plc Triazolo-quinoline derivatives, processes for their preparation and their pharmaceutical use
DE2757929A1 (de) * 1977-12-24 1979-07-05 Boehringer Sohn Ingelheim Neue pyrido-eckige klammer auf 1,2-a eckige klammer zu -v-triazolo- eckige klammer auf 4,5-d eckige klammer zu pyrimidinone, deren salze und verfahren zu deren herstellung
JPS5519292A (en) * 1978-07-24 1980-02-09 Beecham Group Ltd Benzopyranotriazoles*their manufacture and medical composition containing them
DE2966444D1 (en) * 1978-07-24 1984-01-05 Beecham Group Plc Benzopyranotriazoles, preparation of these compounds and pharmaceutical composition containing them
US4431660A (en) 1979-06-11 1984-02-14 Merck & Co., Inc. (4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith
US4349561A (en) * 1979-11-05 1982-09-14 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
DE3169772D1 (de) * 1980-01-19 1985-05-15 Beecham Group Plc Substituted benzopyranotriazoles
IL61897A (en) * 1980-01-19 1984-01-31 Beecham Group Ltd Benzopyrano(2,3-d)-v-triazoles,their production and pharmaceutical compositions containing them
NZ199139A (en) * 1980-12-13 1985-01-31 Beecham Group Ltd Benz(phenoxyalkoxy)-9-oxo-1h,9h-benzopyrano-(2,3-d)-v-triazoles
US4428956A (en) * 1980-12-29 1984-01-31 Merck & Co., Inc. 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
US4431652A (en) * 1980-12-29 1984-02-14 Merck & Co., Inc. 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
JPS57158788A (en) * 1981-03-03 1982-09-30 Beecham Group Ltd Novel compound, manufacture and medicinal composition containing same
WO1993017681A1 (fr) * 1992-03-02 1993-09-16 Abbott Laboratories Antagonistes du recepteur d'angiotensine ii
JPH0717861A (ja) * 1993-07-05 1995-01-20 Sankyo Co Ltd 尿路結石防止剤
DK1026167T3 (da) * 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
JP4075357B2 (ja) * 2001-11-15 2008-04-16 宇部興産株式会社 ４，５−ジ置換−１，２，３−トリアゾール及びその製造法
CN1744899A (zh) * 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0603891D0 (en) * 2006-02-27 2006-04-05 Syngenta Ltd Novel herbicides
US8450350B2 (en) * 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
SG11201407220YA (en) * 2012-06-20 2014-12-30 Hoffmann La Roche N-alkyltriazole compounds as lpar antagonists
TW201418242A (zh) * 2012-10-26 2014-05-16 Du Pont 作為除草劑之經取代的三唑
KR101537296B1 (ko) * 2012-10-26 2015-07-17 삼성전자 주식회사 반도체 나노결정 및 그 제조방법
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
EP3386949A4 (fr) * 2015-12-07 2019-11-20 Wake Forest University Health Sciences Inhibiteurs de glycolate oxydase et méthodes d'utilisation pour le traitement des calculs rénaux
WO2017100268A1 (fr) * 2015-12-07 2017-06-15 Wake Forest University Health Sciences Combinaisons pour le traitement de calculs rénaux
CN105669569B (zh) * 2016-03-03 2017-12-12 武汉工程大学 一种nh‑1,2,3‑三唑化合物的合成方法
CN105541796B (zh) * 2016-03-03 2017-11-14 武汉工程大学 一种nh‑1,2,3‑三唑联吡啶化合物的合成方法
BR112020013073A2 (pt) * 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
EP3986863A4 (fr) * 2019-06-19 2023-01-18 BioMarin Pharmaceutical Inc. Inhibiteurs de glycolate oxydase pour le traitement d'une maladie

Also Published As

Publication number Publication date
TWI811282B (zh) 2023-08-11
KR20200112860A (ko) 2020-10-05
TW202340155A (zh) 2023-10-16
IL297802A (en) 2022-12-01
US11384055B2 (en) 2022-07-12
CN117024420A (zh) 2023-11-10
TW201930272A (zh) 2019-08-01
JP2021509401A (ja) 2021-03-25
CN111788187A (zh) 2020-10-16
RU2020120974A3 (fr) 2022-01-31
JP7344878B2 (ja) 2023-09-14
US20230089374A1 (en) 2023-03-23
MX2022016434A (es) 2023-01-30
PE20201500A1 (es) 2020-12-29
US20230079913A1 (en) 2023-03-16
MX2022016415A (es) 2023-01-30
RU2020120974A (ru) 2022-01-31
IL275496A (en) 2020-08-31
WO2019133770A2 (fr) 2019-07-04
MX2022016427A (es) 2023-01-30
MX2020006414A (es) 2020-09-17
WO2019133770A3 (fr) 2019-08-15
CN117126151A (zh) 2023-11-28
CA3086401A1 (fr) 2019-07-04
AU2018395275A1 (en) 2020-07-16
SG11202005807QA (en) 2020-07-29
JP2023159181A (ja) 2023-10-31
MX2022016463A (es) 2023-02-01
CL2020001742A1 (es) 2021-01-29
IL297788A (en) 2022-12-01
US20210171474A1 (en) 2021-06-10
BR112020013073A2 (pt) 2020-12-01
CN117126152A (zh) 2023-11-28
EP3732167A2 (fr) 2020-11-04
AR114070A1 (es) 2020-07-15
CN117069712A (zh) 2023-11-17
MX2022016422A (es) 2023-01-30
CN117069713A (zh) 2023-11-17

Similar Documents

Publication Publication Date Title
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
MA47719A (fr) Esketamine pour le traitement de la dépression
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA49144A (fr) Polythérapies pour le traitement du cancer
IL275496A (en) Glycolate oxidase inhibitors to treat the disease
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3866781A4 (fr) Nouvelles compositions pour le traitement de maladies inflammatoires
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3740246C0 (fr) Perturbation du complexe linc pour le traitement de laminopathies
EP3766497A4 (fr) Médicament pour le traitement de la toux
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
EP3413898A4 (fr) Utilisation de tréhalose pour le traitement de maladies neurologiques
EP3386949A4 (fr) Inhibiteurs de glycolate oxydase et méthodes d'utilisation pour le traitement des calculs rénaux